StockNews.com downgraded shares of InfuSystem (NYSEAMERICAN:INFU – Free Report) from a strong-buy rating to a buy rating in a research report report published on Tuesday morning.
Separately, Lake Street Capital raised InfuSystem to a strong-buy rating in a report on Thursday, May 9th.
Get Our Latest Stock Analysis on INFU
InfuSystem Stock Down 1.8 %
InfuSystem (NYSEAMERICAN:INFU – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The company had revenue of $33.70 million for the quarter. InfuSystem had a net margin of 0.07% and a return on equity of 0.16%.
Institutional Trading of InfuSystem
Hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers boosted its stake in InfuSystem by 13.8% during the 2nd quarter. Rhumbline Advisers now owns 17,658 shares of the medical instruments supplier’s stock valued at $121,000 after purchasing an additional 2,145 shares during the period. Marshall Wace LLP bought a new stake in InfuSystem during the 2nd quarter valued at approximately $131,000. Oppenheimer Asset Management Inc. boosted its stake in InfuSystem by 52.1% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the medical instruments supplier’s stock valued at $178,000 after purchasing an additional 8,917 shares during the period. Panagora Asset Management Inc. bought a new stake in InfuSystem during the 2nd quarter valued at approximately $208,000. Finally, ARS Investment Partners LLC boosted its stake in InfuSystem by 11.4% during the 2nd quarter. ARS Investment Partners LLC now owns 33,510 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 3,422 shares during the period. Institutional investors own 71.13% of the company’s stock.
About InfuSystem
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Featured Articles
- Five stocks we like better than InfuSystem
- Buy P&G Now, Before It Sets A New All-Time High
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- 5 Top Rated Dividend Stocks to Consider
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- What Are Trending Stocks? Trending Stocks Explained
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.